AccuGenomics, Inc., a U.S.-based leader in next-generation sequencing (NGS) quality standards, and 1Cell.Ai, a U.S.-based precision oncology company specializing in single-cell and liquid biopsy diagnostics, have announced a strategic collaboration to deliver ultra-sensitive, clinically actionable liquid biopsy testing through their clinical laboratory in India, serving cancer patients across Asia.
Under this partnership, 1Cell.Ai will integrate AccuGenomics’ Accukit™ CRC/NSCLC Internal Standards into its OncoIndx panel, an advanced NGS-based assay, to provide per-sample quality control and sensitivity verification. The company anticipates processing tens of thousands of patient samples in the coming year, expanding access to high-precision cancer diagnostics throughout Asia. Additionally, 1Cell.Ai plans to introduce this assay at its Foster City, California facility to support precision multi-omic testing for the U.S. market in the near future.
The Accukit™ CRC/NSCLC Internal Standards are synthetic, gene-specific quality controls designed to validate assay performance and ensure reliable detection of clinically relevant mutations in colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). By embedding these internal standards into every patient sample, laboratories can confirm per-sample analytical accuracy, enhance reproducibility, and minimize false negatives — a crucial improvement for clinical NGS testing, where even small-variant detection can directly influence treatment decisions and patient outcomes.
“We are thrilled to partner with 1Cell.Ai, a leader in multi-omic precision diagnostics,” said Nick Lazaridis, President of AccuGenomics. “By integrating our Accukit™ CRC/NSCLC Internal Standards with their liquid biopsy platform, we are enabling true per-sample sensitivity and reliability, a new benchmark in cancer diagnostics. This collaboration not only strengthens cancer care in India but also lays the groundwork for their expansion into the US market.”
“This collaboration represents a significant step forward in ensuring that every patient sample we analyze meets the highest standards of analytical accuracy,” said Mohan Uttarwar, CEO of 1Cell.Ai. “By integrating AccuGenomics' internal standards into our OncoIndx gene-panel, we can deliver ultra-sensitive, clinically actionable insights for oncologists and patients. This partnership supports our mission to make precision oncology testing both reliable and affordable, first across Asia, and soon in the United States.”
The collaboration between AccuGenomics and 1Cell.Ai underscores a shared commitment to enhancing precision oncology diagnostics through innovation and quality assurance. By combining AccuGenomics’ proven NGS quality standards with 1Cell.Ai’s advanced liquid biopsy technology, the partnership aims to raise global standards in cancer detection and accelerate the availability of affordable, high-accuracy molecular testing for patients worldwide.
Also Read